Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00836082 | A Multiple Dose Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04457845 in Healthy Volunteers | PHASE1 | COMPLETED | 41 | — | — | Feb 1, 2009 | Jul 1, 2009 | Aug 6, 2009 | 1 | Singapore |
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days. |
| Cohort 2 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 1mg per day for 14 days. |
| Cohort 3 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 4mg per day for 14 days. |
| Cohort 4 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 8mg per day for 14 days. |
| Name | Type | Description |
|---|---|---|
| PF-04457845, FAAH inhibitor | DRUG | Oral solution of 0.5mg given once daily for 14 days. |
Inclusion Criteria: * Healthy male and/or female subjects (of non childbearing potential) between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and puls...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | NA | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | — | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | — | Flozin |